ProQR Therapeutics (PRQR) Research & Development (2012 - 2026)
ProQR Therapeutics (PRQR) posted Research & Development of $13.8 million for Q1 2026, down 85.04% sequentially from $92.6 million in Q4 2025, and up 6.85% YoY from $13.0 million in Q1 2025.
ProQR Therapeutics (PRQR) Research & Development (2012 - 2026) Analysis & Trends
ProQR Therapeutics has reported Research & Development for 15 years, with the latest figure at $13.8 million in Q1 2026.
- Quarterly Research & Development rose 6.85% year-over-year to $13.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.6 million (up 31.24% YoY) and the FY2025 annual result came in at $52.1 million, up 34.03% from the prior year.
- Research & Development eased to $13.8 million in Q1 2026 per PRQR's latest filing, from $92.6 million in the prior quarter.
- Over five years, Research & Development peaked at $92.9 million in Q4 2022 and troughed at -$15.5 million in Q3 2022.
- A 5-year average of $12.3 million and a median of -$6.5 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development jumped 751.81% in 2022, then sank 74.39% in 2024.
- Over 5 years, Research & Development stood at $92.9 million in 2022, then sank by 50.69% to $45.8 million in 2023, then surged by 44.91% to $66.4 million in 2024, then jumped by 39.53% to $92.6 million in 2025, then tumbled by 85.04% to $13.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $13.8 million, $92.6 million, and -$13.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 13.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.85 Mn |
| Dec 31, 2025 | 92.59 Mn |
| Sep 30, 2025 | -12.95 Mn |
| Jun 30, 2025 | -12.91 Mn |
| Mar 31, 2025 | 12.96 Mn |
| Dec 31, 2024 | 66.36 Mn |
| Sep 30, 2024 | -10.34 Mn |
| Jun 30, 2024 | -7.59 Mn |
| Mar 31, 2024 | -10.08 Mn |
| Dec 31, 2023 | 45.80 Mn |
| Sep 30, 2023 | -5.93 Mn |
| Jun 30, 2023 | -6.43 Mn |
| Mar 31, 2023 | -6.50 Mn |
| Dec 31, 2022 | 92.88 Mn |
| Sep 30, 2022 | -15.48 Mn |
| Jun 30, 2022 | -12.22 Mn |
| Mar 31, 2022 | -15.00 Mn |
| Dec 31, 2021 | -14.25 Mn |
| Sep 30, 2021 | -13.12 Mn |
| Jun 30, 2021 | -11.72 Mn |